Harbour BioMed Reports Phase II Success of Porustobart in MSS mCRC
China‑based Harbour BioMed (HKG: 2142) announced positive results from its multicenter, open‑label Phase II trial (NCT 05167071)...
Harbour BioMed
HarbourBioMed Reports 327 % Revenue Surge, Launches HCAb‑Based Élancé Therapeutics
Harbour BioMed (HKG: 2142) on Aug. 27, 20025 released its first‑half 2025 financial results, reporting...
Harbour BioMed and Otsuka Pharma Collaborate Globally on BCMAxCD3 Bispecific T-cell Engager
China-based Harbour BioMed (HKG: 2142) has entered into a global strategic collaboration with Japan-headquartered Otsuka...
Harbour BioMed Wins CNIPA Validation of ‘Binding Molecule’ Patent Amid Dispute
China-based Harbour BioMed (HKG: 2142) announced that the China National Intellectual Property Administration (CNIPA) has...
Sichuan Kelun-Biotech Finalizes Licensing Deal for TSLP Monoclonal Antibody
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) announced that it has received the upfront...
Nona Biosciences and Atossa Therapeutics Forge Partnership to Advance Breast Cancer Therapies
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a...
Harbour BioMed Partners with AstraZeneca on Multi-Specific Antibody Development
China-based Harbour BioMed (HKG: 2142) has formed a strategic partnership with UK pharmaceutical giant AstraZeneca...
Harbour BioMed Launches Élancé Therapeutics to Tackle Obesity Treatment Challenges
China-based Harbour BioMed (HKG: 2142) announced the establishment of Élancé Therapeutics, a new subsidiary focused...
Harbour BioMed Appoints Michael D. Patten as Chief Strategy Officer to Lead Global Growth
China-based Harbour BioMed (HKG: 2142) announced the appointment of Michael D. Patten as Chief Strategy...
NewCo Model: China’s Innovative Drug Companies’ New Transaction Mode in Capital Winter
NewCo is a new transaction model developed by Chinese innovative drug companies in response to...
Harbour BioMed Licenses HAT001/HBM9013 to Global Partner for CRH-Targeted Therapy
China-based Harbour BioMed (HKG: 2142) announced a strategic collaboration and licensing agreement with an undisclosed...
Harbour BioMed and Insilico Medicine Partner on AI-Powered Antibody Development
China-based Harbour BioMed (HKG: 2142) announced a strategic partnership with Insilico Medicine, a generative artificial...
Harbour BioMed Receives NMPA Clearance for COPD Treatment HBM9378/SKB378
China-based biopharmaceutical company Harbour BioMed (HKG: 2142) has announced receiving clinical clearance from China’s National...
Harbour BioMed and Kelun Biotech License TSLP Monoclonal Antibody to Windward Bio
Chinese firms Harbour BioMed (HKG: 2142) and Sichuan Kelun Biotech BioPharmaceutical (HKG: 6990) have entered...
Harbour BioMed’s Innovative Antibody Porustobart Shows Promise in Early Clinical Trials for Melanoma
Harbour BioMed (HKG: 2142), a biopharmaceutical company with operations in the United States, the Netherlands,...
Harbour BioMed’s 2024 H1 Revenues Decline Amid R&D Optimization and Pipeline Advancements
Harbour BioMed (HKG: 2142), a biopharmaceutical company with operations in the United States, the Netherlands,...
Harbour BioMed Reclaims Rights to HBM7008 as Cullinan Therapeutics Cancels Licensing Deal
Harbour BioMed (HBM), a biopharmaceutical company with operations in the Netherlands, the United States, and...
Harbour BioMed Resubmits Biological License Application for Batoclimab in China
Harbour BioMed (HKG: 2142), a biopharmaceutical company with operations in the United States, the Netherlands,...
Harbour BioMed Reports Triple-Digit Revenue Growth and First-Ever Net Profit in 2023 Financial Results
Harbour BioMed (HKG: 2142), a biopharmaceutical company with a global presence in Suzhou, China, Cambridge...
Harbour BioMed Partners with Boostimmune to Develop Novel ADC Therapies
Harbour BioMed (HKG: 2142), a biotechnology company with operations in Suzhou, China, Cambridge in the...